ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > DDR1

DDR1

概要

Name:Discoidin domain receptor 1
Target Synonym:Epithelial discoidin domain-containing receptor 1,Epithelial discoidin domain receptor 1,CD167 antigen-like family member A,Cell adhesion kinase,Discoidin receptor tyrosine kinase,HGK2,Mammary carcinoma kinase 10,MCK-10,Protein-tyrosine kinase 3A,Protein-tyrosine kinase RTK-6,TRK E,Tyrosine kinase DDR,Tyrosine-protein kinase CAK,CD167a,CD167 Antigen-Like Family Member A,TRKE,RTK6,PTK3A Protein Tyrosine Kinase 3A,PTK3A,NTRK4,Neurotrophic Tyrosine Kinase, Receptor, Type 4,Neuroepithelial Tyrosine
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Phase 2 Clinical

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
DD1-M5259 Mouse Mouse DDR1 Protein, Fc Tag
DD1-M5259-structure
DD1-M5259-sds
DD1-H82E9 Human Biotinylated Human DDR1 Protein, His,Avitag™ (MALS verified)
DD1-H82E9-structure
DD1-H82E9-sds
DD1-H5258 Human Human DDR1 Protein, Fc Tag
DD1-H5258-structure
DD1-H5258-sds
ACRO Quality

生物活性データの一部

DD1-H82E9-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human DDR1, His,Avitag (Cat. No. DD1-H82E9) on SA Biosensor, can bind Native Human Collagen I protein with an affinity constant of 0.603 nM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).

DD1-H5258-BLI
 DDR1 BLI

Loaded Human DDR1, Fc Tag (Cat. No. DD1-H5258) on Protein A Biosensor, can bind Native Human Collagen I protein with an affinity constant of 0.327 nM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).

Synonym Name

CD167a

Background

Discoidin domain receptor 1 (DDR1) is a member of DDRs, which are members of the receptor tyrosine kinase (RTK). Upon collagen binding, DDR1 undergoes tyrosine autophosphorylation, which consequently triggers downstream genetic and cellular pathways and plays critical roles in the regulation of cellular morphogenesis, differentiation, proliferation, adhesion, migration, and invasion. Research shows that DDR1 is closely related to various human diseases including cancer, fibrosis, atherosclerosis, and other inflammatory disorders. New generation DDR1 inhibitors targeting the allosteric sites outside of the canonical ATP-binding pocket or extracellular domain (allosteric inhibitors) may offer a new opportunity for selective DDR1 inhibition therapy development.

Clinical and Translational Updates

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Merestinib 5OGS5K699E; LY-2801653 Phase 2 Clinical Eli Lilly And Company Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
APL-102 APL-102; CBT-102 Phase 1 Clinical Apollomics Inc Solid tumours Details
PRTH-101 PRTH-101 Phase 1 Clinical The George Washington University Milken Institute School Of Public Health (Gwu), Parthenon Therapeutics Inc Solid tumours; Neoplasms Details
ICP-033 ICP-033 Phase 1 Clinical Beijing Innocare Pharma Tech Co Ltd Solid tumours Details
AVI-4015 AVI-4015 Phase 1 Clinical Avixgen Dry Eye Syndromes Details
AGX-0073 AGX-0073 Phase 1 Clinical Shanghai Aojian Biological Technology Co Ltd Solid tumours Details
Merestinib 5OGS5K699E; LY-2801653 Phase 2 Clinical Eli Lilly And Company Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
APL-102 APL-102; CBT-102 Phase 1 Clinical Apollomics Inc Solid tumours Details
PRTH-101 PRTH-101 Phase 1 Clinical The George Washington University Milken Institute School Of Public Health (Gwu), Parthenon Therapeutics Inc Solid tumours; Neoplasms Details
ICP-033 ICP-033 Phase 1 Clinical Beijing Innocare Pharma Tech Co Ltd Solid tumours Details
AVI-4015 AVI-4015 Phase 1 Clinical Avixgen Dry Eye Syndromes Details
AGX-0073 AGX-0073 Phase 1 Clinical Shanghai Aojian Biological Technology Co Ltd Solid tumours Details

This web search service is supported by Google Inc.

totopphone